Showing 6241-6250 of 8701 results for "".
- Revian Awarded Patent for Biostimulatory Light Combinationshttps://practicaldermatology.com/news/revian-awarded-patent-for-biostimulatory-light-technology/2460249/Revian Inc. has received from the United States Patent and Trademark Office (USPTO) U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the u
- It’s Gold and Silver for Sebacia with Sienna Acquisitionhttps://practicaldermatology.com/news/its-gold-and-silver-for-sebacia-with-sienna-acquisition/2460247/Mr. Chuck Abraham is the new Chief Executive Officer of Sebacia, Inc. Sebacia is preparing a targeted commercial launch of Sebacia Microparticles in the US for treatment of acne early in 2020 with plans to expand to additional territories later in th
- Amorepacific Shows Off Face Mask 3D Printing System and Flexible LED Beauty Device at CES 2020https://practicaldermatology.com/news/amorepacific-shows-off-face-mask-3d-printing-system-and-flexible-led-beauty-device-at-ces-2020/2460246/Amorepacific is presenting its 3D face mask printing system (IOPE Tailored 3D Mask) and flexible LED beauty device (MakeON Flexible LED Patch) at the Consumer Electronics Show 2020 (CES 2020) in Las Vegas. Created in collaboration with the 3D printing system developer Lincsolu
- DermWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://practicaldermatology.com/news/dermwire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2460244/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- Avita Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System in Vitiligohttps://practicaldermatology.com/news/avita-medical-receives-us-fda-investigational-device-exemption-approval-of-clinical-feasibility-study-to-evaluate-recell-system-in-vitiligo/2460240/The U.S. Food and Drug Administration (FDA) approved AVITA Medical’s Investigational Device Exemption (IDE) application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL Autologous Cell Harvesting Device (RECELL System) for repigmentation of depigmen
- BTL Files Patent Infringement Lawsuit Against Allergan and Zimmer Related to Emsculpthttps://practicaldermatology.com/news/btl-files-patent-infringement-lawsuit-against-allergan-and-zimmer-related-to-emsculpt-1/2460239/BTL Aesthetics' US affiliate has filed a lawsuit against Allergan plc, Ireland and its affiliates, and Zimmer MedizinSysteme GmbH, Germany, and its affiliate, in the US Federal District Court for the District of Delaware. The lawsuit asserts
- FDA Approves Ortho Dermatologic’s Arazlo Lotion for Acnehttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-arazlo-lotion-for-acne/2460238/The FDA has approved the New Drug Application for ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. Ortho Dermatologic’s ARAZLO is the first tazarotene acne treatment available in a lotion form,
- Cutera Rolls Out Heroes Among Us Programhttps://practicaldermatology.com/news/cutera-rolls-out-heroes-among-us-program/2460228/Cutera is launching its new “Heroes Among Us” program to showcase patients who’ve been positively affected by Cutera technologies. The new program was launched at the Cutera University Clinical Forum (CUCF) in Scott
- CBD Brands Initiates AD studyhttps://practicaldermatology.com/news/cbd-brands-initiates-ad-study-1/2460226/In the wake of the US Food and Drug Administration’s (FDA) recent revised warning about the risks of CBD products, CBD Brands is initiating a study to investigate a novel cannabidiol lotion for the treatment of atopic dermatitis (AD). The study aims to provide a preliminary assess
- Keloid Breakthrough: Mount Sinai Researchers Show Keloid Shrinkage with Dupilumabhttps://practicaldermatology.com/news/keloid-breakthrough-mount-sinai-researchers-show-keloid-shrinkage-with-dupilumab/2460223/Keloid lesions exhibit increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy, Mount Sinai researchers report. Researchers, led by Emma Guttman-Yassky, MD, PhD, Vice Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York,